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Abstract
Background: The seasonal influenza vaccine coverage rate in China is only 1.9 %. There is no information available
on the economic burden of influenza-associated outpatient visits and hospitalizations at the national level, even
though this kind of information is important for informing national-level immunization policy decision-making.
Methods: A retrospective telephone survey was conducted in 2013/14 to estimate the direct and indirect costs of
seasonal influenza-associated outpatient visits and hospitalizations from a societal perspective. Study participants
were laboratory-confirmed cases registered in the National Influenza-like Illness Surveillance Network and Severe
Acute Respiratory Infections Sentinel Surveillance Network in China in 2013. Patient-reported costs from the survey
were validated by a review of hospital accounts for a small sample of the inpatients.
Results: The study enrolled 529 outpatients (median age: eight years; interquartile range [IQR]: five to 20 years) and
254 inpatients (median age: four years; IQR: two to seven years). Among the outpatients, 22.1 % (117/529) had
underlying diseases and among the inpatients, 52.8 % (134/254) had underlying diseases. The average total costs
related to influenza-associated outpatient visits and inpatient visits were US$ 155 (standard deviation, SD US$ 122)
and US$ 1,511 (SD US$ 1,465), respectively. Direct medical costs accounted for 45 and 69 % of the total costs
related to influenza-associated outpatient and inpatient visits, respectively. For influenza outpatients, the mean cost
per episode in children aged below five years (US$ 196) was higher than that in other age groups (US$ 129–153).
For influenza inpatients, the mean cost per episode in adults aged over 60 years (US$ 2,735) was much higher than
that in those aged below 60 years (US$ 1,417–1,621). Patients with underlying medical conditions had higher costs
per episode than patients without underlying medical conditions (outpatients: US$ 186 vs. US$ 146; inpatients: US$
1,800 vs. US$ 1,189). In the baseline analysis, inpatients reported costs were 18 % higher than those found in the
accounts review (n = 38).
Conclusion: The economic burden of influenza-associated outpatient and inpatient visits in China is substantial,
particularly for young children, the elderly, and patients with underlying medical conditions. More widespread
influenza vaccination would likely alleviate the economic burden of patients. The actual impact and cost-effectiveness
analysis of the influenza immunization program in China merits further investigation.
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Background
Influenza is associated with a substantial disease burden
in China. Records show that between 2010 and 2011,
115 people per 100,000 population with influenza-
related severe acute respiratory infections (SARI) were
hospitalized, with this number increasing to 142 per
100,000 between 2011 and 2012 [1]. The influenza-
related excess mortality rate for respiratory and circula-
tory diseases was estimated at 12.4 and 8.8 per 100,000
in China’s northern and southern cities, respectively [2].
The World Health Organization (WHO)’s Strategic
Advisory Group of Experts on Immunization recom-
mends that annual seasonal influenza vaccination be ad-
ministered to pregnant women, children aged six to
59 months, the elderly, and those with underlying med-
ical conditions [3]. However, China does not currently
have a national government-funded seasonal influenza
immunization program and the cost of vaccination is com-
pletely borne by the vaccinees. Uptake is extremely low;
only 1.9 % of the population was vaccinated during the
2008–2009 influenza season [4]. In order for the influenza
vaccination to be added to the national immunization
schedule and be centrally funded, the National Health and
Family Planning Commission and the Ministry of Finance
need to consider the direct and indirect economic costs of
influenza at the national level.
Several studies have explored the economic burden as-
sociated with seasonal influenza in China [5–9]. How-
ever, all but one [9] looked only at the direct medical
costs and ignored the indirect costs to households and
society due to productivity loss (even though these
should be included according to the China Guidelines
for Pharmacoeconomic Evaluations) [10]. Furthermore,
these studies were all conducted in the tertiary hospitals
of a few highly developed cities, such as Shanghai and
Zhuhai, where costs associated with influenza are likely
to be higher than those in the lower level hospitals in
the more underdeveloped areas of the country [5–9].
To better quantify the economic burden of influenza pa-
tients across mainland China, we conducted a retrospect-
ive telephone survey to systematically assess the direct
and indirect costs of influenza-associated outpatient visits
and hospitalizations from a societal perspective.
Methods
Study design and enrollment of patients
The National Influenza-like Illness (ILI) Surveillance
Network (ILINet) was established to monitor the activity
of, as well as antigenic and genetic changes in, seasonal
influenza viruses in China. This network includes 408
provincial- and prefecture-level Centers for Disease
Control and Prevention (CDCs) and 554 sentinel hospi-
tals situated in 31 provinces. All sentinel hospitals report
the weekly number of ILI cases who seek medical care
in their outpatient departments using the WHO stand-
ard ILI case definition (body temperature ≥38 °C with ei-
ther cough or sore throat) in the absence of an
alternative diagnosis. In each sentinel hospital, respira-
tory specimens are collected daily from the first one or
two reported ILI cases and sent to local CDCs for influ-
enza virus testing using virus isolation and/or reverse
transcription polymerase chain reaction (RT-PCR) [2].
See Additional file 1 for information on the representa-
tiveness of this surveillance network.
The SARI Sentinel Surveillance Network (SARINet)
was launched in 2009 to monitor severe diseases caused
by influenza. It includes 10 tertiary hospitals located in
10 provinces and municipalities (Beijing, Heilongjiang,
Zhejiang, Fujian, Shandong, Hunan, Guangdong, Sichuan,
Yunnan, and Gansu). Respiratory specimens were col-
lected from all inpatients with SARI for influenza virus
testing using virus isolation and/or RT-PCR [7, 11].
We conducted a retrospective telephone survey be-
tween December 25, 2013 and January 11, 2014. Study
participants were patients registered in the National ILI-
Net and SARINet. The aim of the survey was to estimate
the influenza-related direct medical costs (e.g. medica-
tion, examinations), direct non-medical costs (e.g. trans-
portation, accommodation of patients and caregivers),
and indirect costs (patients’ and caregivers’ loss of earn-
ings). All laboratory-confirmed influenza cases or their
caregivers who had telephone numbers registered in ei-
ther the National ILINet or SARINet in 2013 were in-
vited to participate.
Telephone survey and data collection
The telephone surveys were conducted by Ipsos, a mar-
ket research company in China. Well-trained inter-
viewers from Ipsos used a computer-assisted telephone
interviewing system (CATI), which involves using com-
puterized questionnaires to do the interviews over the
telephone and recording the answers directly into a
computer, to conduct the surveys. A research assistant
from the China CDC supervised the interviews. All
phone calls were conducted at an Ipsos call center.
Family caregivers provided information on behalf of
patients aged below 16 years. For other patients, data
were collected from either the patients themselves or
from their family caregivers. After explaining the objec-
tives of the survey, we verified the demographic (e.g.
name, age, gender, address) and clinical (e.g. date of on-
set, hospital visit date) details of each patient. Once this
information was verified and the interviewee was able to
recall a corresponding influenza episode, information
about the costs related to that episode were elucidated.
The questionnaire (see Additional file 2) included ques-
tions on: 1) general health conditions (e.g. having spe-
cific chronic diseases, duration of the corresponding
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influenza episode); 2) costs associated with outpatient
treatment and hospitalization (e.g., number of outpatient
treatments and hospitalizations, length of stay, costs of
prescribed medications and examinations, transportation
and accommodation, number of family caregivers and
days of caring); and 3) cost of self-medication. We asked
respondents to provide total medical costs based on the
amounts specified on their medical bills (which included
both out-of-pocket expenses for medical care as well as
payments by insurers). If respondents could not precisely
recall information such as the duration of hospitalization
or cost, they were asked to provide a range. Each tele-
phone number was dialed up to four times on different
days before being classified as unreachable.
Data analysis
Data analyses were conducted using R version 3.0.3 (R Pro-
ject for Statistical Computing, Vienna, Austria). We calcu-
lated the direct medical, direct non-medical, and indirect
costs stratified by age (<5, 5–14, 15–59, and ≥60 years);
gender; presence of underlying medical conditions associ-
ated with increased risk of hospitalization or death if in-
fected by influenza as listed in the WHO guidelines (these
include chronic obstructive pulmonary disease, asthma, dia-
betes, chronic cardiac disease, chronic renal disease,
chronic liver disease, chronic neurological disease, chronic
hematological disorder, and tuberculosis, etc.) [12]; urban
or rural residence (see Additional file 3 for what classi-
fies an urban or rural area) [13], level of hospital (see
Additional file 4 for definition of hospital levels); geo-
graphic region (Northeast, North, Northwest, East,
Central, Southwest, and South); and virus type (influ-
enza A, influenza B, and influenza untyped).
Transportation costs for those who used private vehi-
cles were estimated by multiplying fuel cost per kilo-
meter (0.650 RMB [14, 15] and 0.055 RMB [16] for
petrol-powered cars and electric vehicles, respectively)
by distance.
Productivity losses of patients and their caregivers
were calculated using the human capital method. The
average daily income per capita in 2013 as the value of
the lost workdays was used. The average daily income
per capita was assumed to be equal to the annual per
capita income in 2013 (stratified by province, and by
rural and urban area) (see Additional file 5) [17] divided
by 365 days. For patients aged below 16 years, the an-
nual per capita income was assumed to be zero. The
cost of school days lost due to illness was not included.
If family caregivers indicated that they took leave from
work to care for patients, this was also considered. All
costs were expressed in US dollars using the exchange
rate in 2013 (1 US$ = 6.1956 CNY) [18].
Despite the skew in sample distributions of costs, the
costs were summarized using the arithmetic mean and
standard deviation (SD) so they could be used in eco-
nomic evaluations [19]. We used the Wilcoxon rank-sum
test or the Kruskal-Wallis test for group comparisons. We
presented medians and interquartile ranges (IQR) of costs
in Additional file 6. For qualitative variables, the chi-square
test was used. We used bootstrap (1,000 replications) mul-
tiple linear regression to analyze the determinants for total
costs. To partially correct for potential non-response bias,
we presented the costs weighted by age group, region, and
level of hospital using the population structure of the Na-
tional ILINet and SARINet as a reference.
On the basis of this cost estimate and the influenza-
associated excess hospitalization rate from hospital-based
SARI surveillance in Jingzhou city, Hubei province [1], we
estimated the population-level economic burden of
influenza-associated hospitalizations in Jingzhou in 2013.
When we compared our estimates with those in previ-
ous studies, we inflated all costs in US dollars in previ-
ous studies for the given year to US dollars in 2013
using the country-specific consumer price index [20].
Sensitivity analysis
As mentioned above, if respondents could not precisely
recall certain details, they were asked to provide ranges
(e.g. costs of prescribed medications and examinations).
The lower limits of these ranges were used in the base-
line analysis to ascertain the economic burden of
influenza-associated outpatient and inpatient visits. We
also conducted a sensitivity analysis to test the impact of
uncertainty on the economic burden of patients by using
the upper limits of the ranges.
Cost validation
In the present study, we used patient-reported medical
costs because of the difficulty of accessing accounts in
all sentinel hospitals. Although patients receive medical
bills that document the total costs including both out-
of-pocket expenses for medical care and costs paid by
insurers, recall bias may have still occurred. To validate
patient-reported costs, we conducted a review of hos-
pital accounts in three selected hospitals (Second Hos-
pital of Fuzhou, Fujian Maternal and Child Health Care
Hospital, and Hunan Provincial People’s Hospital), which
accounted for 5 % of inpatients in our survey. Hospital
accounts were reviewed in March–April 2015 for regis-
tered episodes of these patients.
Ethical considerations
Ethical approval (no. 201417) was obtained from the In-
stitutional Review Board of the China CDC before the
survey began. Verbal informed consent was obtained
from all respondents. For subjects younger than 17 years
of age, parents/legal guardians were requested to give
verbal informed consent.
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Results
Telephone survey
In 2013, a total of 39,968 and 84 laboratory-confirmed
influenza patients were registered in the National ILINet
and SARINet, respectively. Of these, 11,098 and 68 pa-
tients from the National ILINet and SARINet, respect-
ively, had their telephone numbers registered and were
eligible to participate in this survey. We invited all these
patients to participate and successfully interviewed 7.6 %
(839/11,098) and 7.4 % (5/68) patients from the National
ILINet and SARINet, respectively. Reasons for non-
participation included language barriers, unwillingness
to be interviewed, and being unreachable by telephone.
Among the respondents recruited from the National ILI-
Net, 61 were unable to recall a relevant influenza epi-
sode and were thus excluded from the study. In
summary, the subjects for our study comprised five hos-
pitalized cases from the SARINet, and 529 outpatients
and 254 inpatients (inpatients who were hospitalized
within two weeks of outpatient treatment) from the Na-
tional ILINet (see Fig. 1). Figure 2 shows the geographic
distribution of our subjects and the sentinel hospitals
where they sought treatment. The median time
between disease onset and interviews was 46 days
(IQR: 20–103 days).
Demographic characteristics of enrolled patients
Table 1 shows the demographic characteristics of the en-
rolled patients. There were statistically significant differ-
ences in age, region, and hospital level but not in gender
between laboratory-confirmed influenza patients regis-
tered in the surveillance networks who participated in
the study and those who didn’t (see Table 1). From the
783 included patients, 73.7 % were <15 years old, 54.7 %
were male, 60.7 % were from tertiary hospitals, and
77.8 % were from urban areas. Almost half of the pa-
tients (47.8 %) resided in East China. The median ages
of participating influenza outpatients and inpatients
were eight years (IQR: five to 20 years) and four years
(IQR: two to seven years), respectively. A larger propor-
tion of inpatients (52.8 % [134/254]) had underlying dis-
eases than outpatients (22.1 % [117/529]). The mean
number of outpatient department visits was 2.1 (SD 1.7).
Among the influenza inpatients, 12.6 % (n = 32) were
hospitalized more than once; the average number of
hospitalizations was 1.2 (SD 0.6) and the average
Fig. 1 Flow chart showing the number of influenza patients included in the study
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duration of hospitalization was 9.0 (SD 4.9) days. The
average lengths of stay were 7.7 (SD 3.6) days, 8.2 (SD
3.7) days, and 7.9 (SD 3.3) days for the first, second, and
third hospitalization, respectively.
Economic burden of influenza-associated outpatient visits
The mean cost per episode for influenza outpatients was
US$ 155 (SD 122), consisting of US$ 70 (SD 69) for direct
medical costs, US$ 26 (SD 44) for direct non-medical costs,
and US$ 59 (SD 59) for indirect costs (see Table 2). The
cost weighted by population structure (by age group, re-
gion, and level of hospital) of patients registered in the Na-
tional ILINet was US$ 159 (SD 240), consisting of US $75
(SD 127) for direct medical costs, US $26 (SD 67) for direct
non-medical costs, and US $58 (SD 86) for indirect costs.
The median costs (see Additional file 6) were lower than
the mean costs.
Mean cost per episode was significantly higher (p < 0.05)
in patients with underlying medical conditions, urban pa-
tients, and patients who sought treatment in tertiary hos-
pitals. There were also significant (p < 0.05) differences
between age groups (with the highest cost observed in
those aged below five years) and region (with higher costs
observed in Northwest and East China). No significant as-
sociation was observed between cost and gender or influ-
enza virus type. In the multiple linear regression analysis,
underlying diseases, age, region, and level of hospital were
significantly associated with the total cost per episode (p <
0.05). The presence of underlying illnesses was found to
increase the total cost per episode by US$ 40 (95 % confi-
dence interval, 95 % CI 16–76). Seeking medical care in
primary hospitals was found to decrease the total cost per
episode by US$ 34 (95 % CI 10–61). Compared to the
costs of outpatients from East China, the costs of outpa-
tients from North, Central, South, and Southwest China
were lower by US$ 38–64. Age was negatively associated
with the total cost (see Table 2).
Economic burden of influenza-associated hospitalizations
Inpatient costs were nearly nine times greater than out-
patient costs, with an average cost per episode of US$
1,511 (SD 1,465), consisting of US $1,038 (SD 1,315) for
direct medical costs, US$ 277 (SD 288) for direct non-
medical costs, and US$ 197 (SD 169) for indirect costs
Fig. 2 Geographic distribution of participating patients and the sentinel hospitals where they sought treatment. a: Geographic distribution of the
sentinel hospitals where the participating patients were registered. b: Geographic distribution of participating influenza outpatients from rural
areas. c: Geographic distribution of participating influenza outpatients from urban areas. d: Geographic distribution of participating influenza
inpatients from rural areas.E: Geographic distribution of participating influenza inpatients from urban areas
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(see Table 3). The weighted cost was US$ 1,605 (SD
2,446), consisting of US$ 1,119 (SD 2,051) for direct
medical costs, US$ 283 (SD 401) for direct non-medical
costs, and US$ 203 (SD 308) for indirect costs.
Direct medical costs for inpatients constituted a larger
proportion of the total costs than for outpatients (69 %
vs. 45 %). Inpatient costs (urban: US$ 1,486; rural: US$
1,620) corresponded to 31 and 113 % of the annual per
capita income in urban (US$ 4,769) and rural (US$
1,436) areas, respectively. There were significant differ-
ences in costs in terms of underlying medical conditions
(p < 0.05). Although the differences of total costs were
not observed among geographic regions, the indirect
costs in East China (mean US$ 253) were significantly
higher than those in other regions (mean US$ 148–212)
(p < 0.05). Multiple linear regression analysis revealed
that underlying illnesses increased the total cost per epi-
sode by US$ 617 (95 % CI 293–1,290) (see Table 3).
The economic burden of influenza-associated hospital-
izations in Jingzhou, Hubei province was US$ 8.64–
10.04 million among children ≤ five years of age, US$
2.15–3.41 million among the elderly, and US$ 14.99–
17.31 million among the total population (n = 5.71 mil-
lion) in 2013. Young children and the elderly accounted
for over 70 % of this burden.
Sensitivity analysis on the economic burden of influenza-
associated outpatient visits and hospitalization
We found that 35.3 and 60.6 % of outpatient and inpatient
interviewees, respectively, were unable to precisely recall
at least one piece of information about costs and gave
ranges instead. When the upper limits rather than the
lower limits of the ranges (which were used in the baseli-
neanalysis above) were used, the total costs rose by 12 and
8 % for outpatients and inpatients, respectively.
Cost validation
All 38 patients in the cost validation survey were youn-
ger than 16 years of age and came from tertiary hospi-
tals. Among them, 84.0 % were urban residents.
Differences in characteristics of inpatients by gender,
underlying diseases, and length of stay in hospital were
not significant between the cost validation survey and
telephone study (p > 0.05). For these patients, the aver-
age direct medical costs obtained from the telephone
survey in the baseline analysis (US$ 977, SD 636) and in
the sensitivity analysis (US$ 1,076, SD 828) were 18 and
30 % higher, respectively, than those obtained from the
medical records (US$ 830, SD 456). When we adjusted
for recall bias for costs in the baseline analysis, the costs
Table 1 Characteristics of included patients and other lab-confirmed influenza patients from surveillance networks in the survey
Characteristic Included patients
in the survey
Other lab-confirmed influenza patients
from surveillance networks
Test for difference
in groups
p-value
(n = 783) (n = 39269)
Median age, years (inter-quartile range) 7 (3–15) 9 (4–27) Rank-sum test <0.001
Age group, years (%) Chi-square test <0.001
< 5 266 (34.0) 11854 (30.2)
5–14 311 (39.7) 12113 (30.8)
15–59 187 (23.9) 13653 (34.8)
≥ 60 19 (2.4) 1649 (4.2)
Male (%) 428 (54.7) 21568 (54.9) Chi-square test 0.913
Region (%) Chi-square test <0.001
North China 45 (5.7) 4181 (10.6)
Northeast China 3 (0.4) 2000 (5.1)
East China 374 (47.8) 13136 (33.5)
Central China 119 (15.2) 5132 (13.1)
South China 95 (12.1) 7190 (18.3)
Southwest China 92 (11.7) 4470 (11.4)
Northwest China 55 (7.0) 3160 (8.0)
Hospital (%) Chi-square test <0.001
Level 1 and lower 131 (16.7) 2666 (6.8)
Level 2 177 (22.6) 9964 (25.4)
Level 3 475 (60.7) 26623 (67.8)
Unknown 0 (0) 16 (0)
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came to be US$ 131 and US$ 1,281 for outpatients and
inpatients, respectively.
Discussion
Our retrospective telephone survey found that sea-
sonal influenza poses a substantial economic burden
for patients in mainland China, particularly for young
children, the elderly, and patients with underlying
medical conditions. The mean costs per influenza epi-
sode for outpatients and inpatients were US$ 155 (SD
122) and US$ 1,511 (SD 1,465), respectively. Costs as-
sociated with urban and rural inpatients corresponded
to 31 and 113 % of the annual per capita income in
urban and rural areas, respectively. Considering only
influenza hospitalizations, we found that the eco-
nomic burden of patients in Jingzhou city (which has
Table 2 Costs per episode for influenza outpatients and associated risk factors in China, 2013 (US$)a
Characteristic Direct cost Indirect costs Total costs Multiple linear regression
Medical costs Non-medical costs (95 % Confidence interval)b
Total (n = 529) 70 (69) 26 (44) 59 (59) 155 (122)
Gender p = 0.141 p = 0.904 p = 0.333 p = 0.814
Female (n = 248) 64 (52) 28 (49) 62 (65) 153 (116) Reference
Male (n = 281) 75 (81) 25 (40) 57 (52) 157 (127) −6 (−24,12)
Age group (years) p = 0.062 p < 0.001 p = 0.006 p = 0.003
< 5 (n = 122) 85 (84) 36 (53) 75 (75) 196 (152) Reference
5–14 (n = 232) 63 (68) 28 (43) 61 (61) 153 (121) −52 (−89,−22)f
15–59 (n = 160) 68 (59) 17 (39) 45 (34) 130 (91) −81 (−119,−52)f
≥ 60 (n = 15) 61 (41) 10 (13) 58 (41) 129 (62) −104 (−151,−63)f
Risk statusc p=0.006 p=0.228 p=0.163 p=0.009
Low risk (n = 412) 64 (57) 26 (44) 57 (54) 146 (111) Reference
High risk (n = 117) 90 (98) 28 (45) 68 (71) 186 (151) 40 (16,76)f
Area p= 0.197 p= 0.406 p < 0.001 p < 0.001
Urban area (n = 438) 69 (62) 25 (42) 67 (61) 161 (119) Reference
Rural area (n = 91) 72 (96) 33 (56) 23 (23) 128 (132) −26 (−53,14)
Region p = 0.013 p = 0.403 p < 0.001 p = 0.004
East China (n = 292) 72 (67) 26 (48) 71 (64) 169 (124) Reference
North China (n = 17)d 82 (53) 13 (20) 38 (19) 133 (78) −45 (−95,−3)f
Central China (n = 52) 69 (65) 20 (27) 40 (36) 129 (95) −64 (−98,−31)f
South China (n = 64) 48 (45) 27 (45) 45 (37) 120 (100) −51 (−78,−22)f
Southwest China (n = 68) 65 (48) 26 (37) 50 (67) 140 (103) −38 (−68,−8)f
Northwest China (n = 36) 97 (132) 38 (52) 44 (46) 179 (191) −5 (−52,71)
Hospital p < 0.001 p = 0.745 p = 0.002 p = 0.002
Level 3 (n = 298) 73 (60) 28 (50) 66 (67) 167 (124) Reference
Level 2 (n = 119) 78 (100) 22 (35) 56 (45) 156 (138) 3 (−21,33)
Level 1 and lower (n = 112) 51 (48) 26 (38) 45 (43) 122 (88) −34 (−61,−10)f
Virus type p = 0.868 p = 0.973 p = 0.220 p = 0.565
Untypede (n = 307) 71 (79) 25 (42) 60 (62) 157 (130) Reference
Influenza A (n = 164) 67 (53) 27 (50) 61 (56) 156 (106) −10 (−31,13)
Influenza B (n = 58) 70 (57) 27 (42) 47 (41) 144 (119) 2 (−25,41)
aMean (standard deviation) was presented to facilitate their use in economic evaluations despite the skew in sample distributions of costs. However, Rank-sum test
was used for comparing two samples, and Kruskal-Wallis test was used for comparing three or more groups because the cost distribution is too right skewed
bCompared to the reference, absolute increase or decrease of the total cost (in US$). And we obtained the bias-corrected and accelerated (BCa) bootstrap percentile
confidence interval using the R function “boot.ci”
cRisk status: high risk patients refer to those with underlying medical conditions including: chronic respiratory disease, asthma, chronic cardiovascular diseases,
diabetes, chronic liver disease, and chronic renal disease, etc. Other patients without these underlying diseases are low risk patients
dNorth China: 2 patients from Northeast China were grouped into North China
eUntyped: Laboratory tests for influenza virus type identification were not conducted
fp < 0.05: significant differences
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0.42 % of China’s population) was US$ 14.99–17.31
million in 2013. We are now conducting a survey to
estimate the influenza-related outpatient incidence in
China so we can get an accurate picture of the total
economic burden associated with influenza at the na-
tional level.
Influenza mostly affected children aged below five
years, the elderly, and those with underlying diseases.
Among the outpatients, costs were highest for children
aged below five years (US$ 196 vs. US$ 129–153 for
other age groups). Among the inpatients, costs were
highest among those aged 60 years or above (US$ 2,735
Table 3 Costs per episode for influenza inpatients and associated risk factors in China, 2013 (US$)a
Characteristic Direct cost Indirect costs Total cost Multiple linear regression
Medical cost Non-medical cost (95 % Confidence interval)b
Total (n = 254) 1038 (1315) 277 (288) 197 (169) 1511 (1465)
Gender p=0.479 p=0.863 p=0. 295 p=0. 707
Female (n = 107) 1131 (1794) 295 (361) 201 (160) 1627 (1927) Reference
Male (n = 147) 969 (806) 263 (220) 194 (176) 1427 (1004) −215 (−688,116)
Age group (years) p < 0.001 p = 0.046 p = 0. 018 p < 0.001
< 5 (n = 144) 980 (775) 315 (336) 213 (178) 1508 (1021) Reference
5–14 (n = 79) 1031 (2014) 229 (197) 157 (150) 1417 (2112) −52 (−402,566)
15–59 (n = 27) 1175 (899) 219 (207) 227 (168) 1621 (1059) 88 (−529,639)
≥ 60 (n = 4) 2300 (1539) 230 (234) 205 (73) 2735 (1821) 88 (−529,639)c
Risk statusd p < 0.001 p=0.001 p < 0.001 p < 0.001
Low risk (n = 120) 810 (661) 220 (179) 159 (132) 1189 (814) Reference
High risk (n = 134) 1241 (1677) 328 (351) 231 (190) 1800 (1820) 617 (293,1290)f
Area p = 0. 797 p = 0. 285 p < 0.001 p = 0.330
Urban area (n = 171) 949 (760) 259 (270) 251 (177) 1486 (958) Reference
Rural area (n = 83) 1221 (2022) 313 (320) 86 (70) 1620 (2169) 190 (−170,950)
Region p = 0.041 p = 0.518 p = 0.020 p = 0.089
East China (n = 82) 888 (749) 293 (362) 253 (215) 1433 (1019) Reference
North China (n = 31)e 1256 (930) 350 (339) 212 (149) 1817 (1132) 505 (−15,1163)
Central China (n = 67) 983 (919) 252 (232) 162 (138) 1397 (1150) 26 (−310,456)
South China (n = 31) 896 (655) 251 (224) 172 (137) 1318 (833) −135 (−576,308)
Southwest China (n = 24) 892 (986) 237 (197) 148 (119) 1277 (1157) −82 (−582,513)
Northwest China (n = 19) 1935 (3766) 267 (193) 158 (109) 2360 (3809) 1076 (−118,4562)
Hospital p = 0.022 p = 0.400 p = 0. 182 p = 0.040
Level 3 (n = 177) 1090 (1422) 270 (240) 203 (168) 1563 (1527) Reference
Level 2 (n = 58) 894 (750) 283 (401) 202 (189) 1379 (1065) −83 (−618,261)
Level 1 and lower (n = 19) 989 (1633) 316 (303) 130 (93) 1436 (1925) −213 (−1362,1101)
Virus type p = 0.300 p = 0.029 p = 0.074 p = 0.178
Untypedg (n = 184) 1083 (1462) 292 (294) 212 (182) 1587 (1611) Reference
Influenza A (n = 34) 953 (969) 222 (201) 171 (132) 1346 (1114) −98 (−536,320)
Influenza B (n = 36) 887 (636) 250 (321) 145 (112) 1282 (817) −481 (−996,−69)f
aMean (standard deviation) was presented to facilitate their use in economic evaluations despite the skew in sample distributions of costs. However, Rank-sum test
was used for comparing two samples, and Kruskal-Wallis test was used for comparing three or more groups because the cost distribution is too right skewed
bCompared to the reference, absolute increase or decrease of the total cost (in US$). And we obtained the bias-corrected and accelerated (BCa) bootstrap percentile
confidence interval using the R function “boot.ci”
c4 patients in the ≥60 age group were grouped into 15–59 years of age group in the multivariable linear regression analysis
dRisk status: high risk patients refer to those with underlying medical conditions including: chronic respiratory disease, asthma, chronic cardiovascular diseases,
diabetes, chronic liver disease, and chronic renal disease, etc. Other patients without these underlying diseases are low risk patients
eNorth China: 1 patients from Northeast China were grouped into North China
fp < 0.05: significant differences
gUntyped: Laboratory tests for influenza virus type identification were not conducted
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vs. US$ 1,417–1,621 for other age groups). We found
that young children and the elderly accounted for over
70 % of the economic burden of influenza-associated
hospitalizations in Jingzhou in 2013. In agreement with
previous studies [6, 7], our study indicated that both inpa-
tients and outpatients with underlying medical conditions
had higher economic burdens than patients without under-
lying medical conditions. The presence of underlying ill-
nesses was found to increase the total cost per influenza
episode by US$ 40 (95 % CI 16–76) and US$ 617 (95 % CI
293–1,290) for outpatients and inpatients, respectively.
This finding supports the current influenza immunization
policies in China, as well as the WHO recommendations,
which advise on the immunization of young children, the
elderly, and those in clinical risk groups.
Our estimates of influenza-related direct inpatient costs
were similar to those of a study done in Hong Kong (US$
1,523–1,661) [21], but much lower than those reported in
the US study (US$ 13,768–103,252) [22]. Our direct out-
patient medical cost estimates were also lower than the fig-
ures in the US study (US$ 120–928) [22]. Differences in
costs could be partially due to differences in study method-
ologies. For example, the US study included all cases with
pneumonia and influenza diagnostic codes rather than just
laboratory-confirmed influenza patients. Also, costs were
extracted from a health insurance claims database for a
much longer period (two weeks prior to the date of admis-
sion to 30 days post-discharge) [22]. Apart from this, the
differences may be explained by actual differences in
healthcare labor costs between the two countries, as well
as in healthcare financing (as patients in China have to pay
out-of-pocket for a larger portion of the total medical costs
than in the US) [23].
The study in the US reported that indirect costs (prod-
uctivity losses) were about 10 times higher than direct
medical costs [22]. However, our survey found that dir-
ect medical costs were the dominant cost driver for in-
fluenza patients in China. Differences in methodology
and income may in part account for this discrepancy. For
example, in the US study, days of productivity loss were
calculated using the average daily wage of US$ 145 [22],
which is much higher than our estimates of US$ 12 and
US$ 4 for urban and rural areas of China, respectively.
Prior to our study, several regional studies have been
published on the economic burden associated with
laboratory-confirmed influenza cases in China (by
checking medical records). As mentioned above, the
mean costs obtained from the telephone survey were
18 % higher than those obtained from medical records.
Accordingly, we decreased our costs by 18 % when we
compared the region-specific costs with previous esti-
mates. Direct outpatient medical costs estimated in our
study were similar to those reported in a previous study
done in Zhuhai city, Guangdong province (mean: US$
28.0 vs. US$ 26.0) [5], while the direct inpatient medical
costs were 1.5 times greater than those reported in a
study conducted in the provincial capitals of Sichuan,
Hunan, and Shandong provinces [7]. Some of the differ-
ences in costs may partially stem from variations in
patient characteristics. For instance, in the Sichuan,
Hunan, and Shandong study, the proportion of included
patients with underlying medical conditions was only
20.8 %, much lower than in our study (46.0 %) [7]. When
using the same weights for the proportion of the popula-
tion with underlying diseases, the direct inpatient med-
ical costs in the previous study were similar to that in
our study (US$ 858 vs. US$ 891). Only one previous
study assessed influenza-related indirect costs. This
study, done in Suzhou city, Jiangsu province, reported
indirect costs of US$ 40.8 for illness in children aged
below five years in the outpatient setting [9], which was
lower than our estimation (US$ 50.8).
Our study had several limitations. First, as it was a
retrospective study, recall bias was inevitable. To
minimize its effect, we selected each participant’s most
recent influenza episode. The time between the influ-
enza episode and interview was less than 46 days for
50 % of our study participants. To partially test for recall
bias, we conducted a sensitivity analysis and a cost valid-
ation survey. The sensitivity analysis found that the
lower limits of ranges of costs reported by patients were
relatively closer to the actual cost than the upper limits.
Despite this, the lower limits of the cost ranges over-
stated the actual costs by 18 %.
Second, our samples were from the National ILINet
and SARINet. There were statistically significant differ-
ences in age, region, and hospital level between influenza
patients who participated in the present study and those
who didn’t. To generalize our results to represent the
costs of all influenza patients registered in the National
ILINet and SARINet, we weighted the costs by age
group, region, and level of hospital using the population
structure of the surveillance networks as a reference.
The weighted costs increased by 2.6 and 6.2 % for influ-
enza outpatients and inpatients, respectively. This revealed
that the differences in demographic characteristics did not
have much of an impact on costs. However, due to a lack
of characteristics of influenza patients at the national level,
we couldn’t precisely determine whether our sample rep-
resents all influenza patients in China. Instead, we evalu-
ated the representativeness of hospitals in the National
ILINet and SARINet for all medical institutions in China.
This could partially account for the representativeness of
our samples. We found that the high-level hospitals were
overrepresented in the National ILI and SARI sentinel hos-
pitals, and that the two surveillance systems do not cover
basic medical institutions (see Additional file 1). Patients
with severe influenza are more likely to seek medical help
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in high-level hospitals, while patients with mild influenza
prefer basic medical institutions or practice self-care at
home. As such, patients with severe influenza may be
overrepresented in our survey, which may result in an
overestimation of the economic burden associated with in-
fluenza outpatient visits and hospitalizations. Finally, only
15 outpatients and four inpatients were over 60 years of
age. Hence, the estimation of influenza-related economic
burden of elderly patients may not be totally accurate.
Despite these limitations, the present study provides a
more nationally representative cost estimate than previous
studies, as well as a comprehensive assessment of both the
direct and indirect costs of influenza outpatients and inpa-
tients in China. Characterizing the economic burden asso-
ciated with influenza is a cornerstone of cost-effectiveness
studies, which are crucial for policy decision-making in
influenza vaccination programs. A previous systematic
review showed that 43 % of cost-effectiveness studies
(22/51) reported that influenza vaccination saves costs,
and the majority of the remaining studies reported that
influenza vaccination was cost-effective, with cost-
effectiveness ratios below $50,000/QALY (quality-adjusted
life-year) [24]. These studies demonstrate that influenza
vaccination is economically favorable for children and the
elderly [24]. Although a comprehensive cost-effectiveness
analysis of influenza vaccination is still lacking in main-
land China, conclusions from studies and reviews done in
other countries consistently suggest that influenza vaccin-
ation is likely to be cost-effective. The present study forms
the basis to conduct cost-effectiveness analyses in the
future, in order to assess the reduction in disease and eco-
nomic burden associated with widespread seasonal influ-
enza vaccination in China.
Conclusion
Our survey found that the economic burden of influenza-
associated outpatient and inpatient visits in China is sub-
stantial, particularly for young children, the elderly, and
patients with underlying medical conditions. A recent sys-
tematic review found that information about costs associ-
ated with influenza and cost-effectiveness of influenza
vaccination is severely lacking in low- and middle-income
countries [24]. Our study is important to fill this evidence
gap, as well as to provide information on the burden of
disease and the cost-effectiveness of seasonal influenza
vaccination in China and other middle-income countries.
Such studies are vital for informing evidence-based
decision-making in vaccination policies in these settings.
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